These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 20422263)
1. In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia. Amann LC; Gandal MJ; Lin R; Liang Y; Siegel SJ Pharm Res; 2010 Aug; 27(8):1730-7. PubMed ID: 20422263 [TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo demonstration of risperidone implants in mice. Rabin C; Liang Y; Ehrlichman RS; Budhian A; Metzger KL; Majewski-Tiedeken C; Winey KI; Siegel SJ Schizophr Res; 2008 Jan; 98(1-3):66-78. PubMed ID: 17765477 [TBL] [Abstract][Full Text] [Related]
3. Microsphere delivery of Risperidone as an alternative to combination therapy. D'Souza S; Faraj J; DeLuca P Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):631-9. PubMed ID: 23892159 [TBL] [Abstract][Full Text] [Related]
4. In vitro-in vivo correlation of parenteral risperidone polymeric microspheres. Shen J; Choi S; Qu W; Wang Y; Burgess DJ J Control Release; 2015 Nov; 218():2-12. PubMed ID: 26423236 [TBL] [Abstract][Full Text] [Related]
5. A novel risperidone-loaded SAIB-PLGA mixture matrix depot with a reduced burst release: effects of solvents and PLGA on drug release behaviors in vitro/in vivo. Lin X; Yang S; Gou J; Zhao M; Zhang Y; Qi N; He H; Cai C; Tang X; Guo P J Mater Sci Mater Med; 2012 Feb; 23(2):443-55. PubMed ID: 22170300 [TBL] [Abstract][Full Text] [Related]
6. Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation. Su ZX; Shi YN; Teng LS; Li X; Wang LX; Meng QF; Teng LR; Li YX Pharm Dev Technol; 2011 Aug; 16(4):377-84. PubMed ID: 20370594 [TBL] [Abstract][Full Text] [Related]
7. Asenapine maleate in situ forming biodegradable implant: an approach to enhance bioavailability. Avachat AM; Kapure SS Int J Pharm; 2014 Dec; 477(1-2):64-72. PubMed ID: 25305379 [TBL] [Abstract][Full Text] [Related]
8. Formulation and evaluation of PLA and PLGA in situ implants containing secnidazole and/or doxycycline for treatment of periodontitis. Gad HA; El-Nabarawi MA; Abd El-Hady SS AAPS PharmSciTech; 2008; 9(3):878-84. PubMed ID: 18654864 [TBL] [Abstract][Full Text] [Related]
9. Development of intranasal implantable devices for schizophrenia treatment. Utomo E; Domínguez-Robles J; Moreno-Castellanos N; Stewart SA; Picco CJ; Anjani QK; Simón JA; Peñuelas I; Donnelly RF; Larrañeta E Int J Pharm; 2022 Aug; 624():122061. PubMed ID: 35908633 [TBL] [Abstract][Full Text] [Related]
10. Sustained release of risperidone from biodegradable microspheres prepared by in-situ suspension-evaporation process. An T; Choi J; Kim A; Lee JH; Nam Y; Park J; Sun Bk; Suh H; Kim CJ; Hwang SJ Int J Pharm; 2016 Apr; 503(1-2):8-15. PubMed ID: 26899975 [TBL] [Abstract][Full Text] [Related]
11. An Accelerated Release Method of Risperidone Loaded PLGA Microspheres with Good IVIVC. Hu X; Zhang J; Tang X; Li M; Ma S; Liu C; Gao Y; Zhang Y; Liu Y; Yu F; Yang Y; Guo J; Li Z; Mei X Curr Drug Deliv; 2018; 15(1):87-96. PubMed ID: 28521697 [TBL] [Abstract][Full Text] [Related]
12. Effects of formulation parameters on encapsulation efficiency and release behavior of risperidone poly(D,L-lactide-co-glycolide) microsphere. Su Z; Sun F; Shi Y; Jiang C; Meng Q; Teng L; Li Y Chem Pharm Bull (Tokyo); 2009 Nov; 57(11):1251-6. PubMed ID: 19881277 [TBL] [Abstract][Full Text] [Related]
13. Towards in vitro - In vivo correlation models for in situ forming drug implants. Wang X; Roy M; Wang R; Kwok O; Wang Y; Wang Y; Qin B; Burgess DJ J Control Release; 2024 Aug; 372():648-660. PubMed ID: 38936743 [TBL] [Abstract][Full Text] [Related]
14. Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol. Ahmed TA; Ibrahim HM; Ibrahim F; Samy AM; Kaseem A; Nutan MT; Hussain MD J Pharm Sci; 2012 Oct; 101(10):3753-62. PubMed ID: 22753324 [TBL] [Abstract][Full Text] [Related]
15. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Panyam J; Labhasetwar V Adv Drug Deliv Rev; 2003 Feb; 55(3):329-47. PubMed ID: 12628320 [TBL] [Abstract][Full Text] [Related]
16. Improved lysozyme stability and release properties of poly(lactide-co-glycolide) implants prepared by hot-melt extrusion. Ghalanbor Z; Körber M; Bodmeier R Pharm Res; 2010 Feb; 27(2):371-9. PubMed ID: 20033474 [TBL] [Abstract][Full Text] [Related]
17. In vivo characterization of Perseris and compositionally equivalent formulations. Wang X; Bao Q; Wang R; Li T; Wang Y; Qin B; Li Q; Burgess DJ Int J Pharm; 2023 Jul; 642():123170. PubMed ID: 37354927 [TBL] [Abstract][Full Text] [Related]
18. In vitro-in vivo correlation of parenteral PLGA microspheres: Effect of variable burst release. Andhariya JV; Jog R; Shen J; Choi S; Wang Y; Zou Y; Burgess DJ J Control Release; 2019 Nov; 314():25-37. PubMed ID: 31654687 [TBL] [Abstract][Full Text] [Related]